Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -47,9 M
Net income 2017 -48,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,73 M
EBIT 2018 -53,8 M
Net income 2018 -45,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 1,90x
Capitalization 16,6 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.It... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
06/19 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Change..
05/25 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
05/25 ANTHERA PHARMACEUTICALS INC : Other Events (form 8-K)
05/18 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Notice of Delisting or..
05/18 ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
05/15 Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical S..
05/10 ANTHERA PHARMACEUTICALS : reports 1Q loss
05/10 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
05/10 Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quar..
05/01 ANTHERA PHARMACEUTICALS INC : REVERSE SPLIT: 1 for 8
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 5
Average target price 6,85 $
Spread / Average Target 315%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
Charles V. Olson Chief Technology Officer
William R. Shanahan Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR17
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..40.93%54 987
VERTEX PHARMACEUTICALS81.21%33 251
More Results